Investigational group
®
Envarsus® will be supplied by the sponsor for the duration of the 12-week controlled treatment phase. Envarsus® will not be supplied for the follow-up phase (Table IMP-characteristics of Envarsus®Envarsus® therapy should commence at a starting dose of 0.11–0.13 mg/kg/day.In case the patient initially received an oral formulation of Prograf® during the run-in phase (e.g. administered via nasogastric tubing), conversion should be performed on a 1:0.7 (mg to mg) total daily dose basis. In case the patient initially received intravenous Prograf® therapy (continuous 24-h infusion) during the run-in phase at a dose approximately 1/5th of the recommended oral dose, the conversion to Envarsus® should be modified accordingly.